144 related articles for article (PubMed ID: 18442635)
1. Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice.
Matsumoto M; Tanimoto M; Gohda T; Aoki T; Murakoshi M; Yamada K; Yamazaki T; Kaneko S; Horikoshi S; Tomino Y
Metabolism; 2008 May; 57(5):691-7. PubMed ID: 18442635
[TBL] [Abstract][Full Text] [Related]
2. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
3. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.
Fujii M; Inoguchi T; Maeda Y; Sasaki S; Sawada F; Saito R; Kobayashi K; Sumimoto H; Takayanagi R
Kidney Int; 2007 Aug; 72(4):473-80. PubMed ID: 17568784
[TBL] [Abstract][Full Text] [Related]
4. Thymosin β4 attenuates early diabetic nephropathy in a mouse model of type 2 diabetes mellitus.
Zhu J; Su LP; Zhou Y; Ye L; Lee KO; Ma JH
Am J Ther; 2015; 22(2):141-6. PubMed ID: 23846524
[TBL] [Abstract][Full Text] [Related]
5. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice.
Mitsuhashi T; Uemoto R; Ishikawa K; Yoshida S; Ikeda Y; Yagi S; Matsumoto T; Akaike M; Aihara KI
J Atheroscler Thromb; 2018 Jan; 25(1):65-80. PubMed ID: 28592707
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice.
Tanimoto M; Fan Q; Gohda T; Shike T; Makita Y; Tomino Y
Metabolism; 2004 Nov; 53(11):1473-9. PubMed ID: 15536604
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol.
Mori Y; Hirano T
Metabolism; 2012 Mar; 61(3):379-88. PubMed ID: 21868047
[TBL] [Abstract][Full Text] [Related]
9. Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice.
Aoki T; Kaneko S; Tanimoto M; Gohda T; Hagiwara S; Murakoshi M; Ishikawa Y; Furukawa M; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2012; 25(1):127-36. PubMed ID: 21725918
[TBL] [Abstract][Full Text] [Related]
10. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y
Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
[TBL] [Abstract][Full Text] [Related]
11. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Yagi S; Aihara K; Ikeda Y; Sumitomo Y; Yoshida S; Ise T; Iwase T; Ishikawa K; Azuma H; Akaike M; Matsumoto T
Circ Res; 2008 Jan; 102(1):68-76. PubMed ID: 17967781
[TBL] [Abstract][Full Text] [Related]
13. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells.
Wang J; Tokoro T; Matsui K; Higa S; Kitajima I
Life Sci; 2005 Mar; 76(19):2257-68. PubMed ID: 15733940
[TBL] [Abstract][Full Text] [Related]
14. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
15. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients.
Miyashita Y; Endo K; Saiki A; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
J Atheroscler Thromb; 2009 Oct; 16(5):539-45. PubMed ID: 19907100
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.
Huang CH; Huang YY; Hsu BR
J Diabetes Investig; 2016 Sep; 7(5):769-76. PubMed ID: 27181110
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S
Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production.
Shinozaki K; Nishio Y; Ayajiki K; Yoshida Y; Masada M; Kashiwagi A; Okamura T
J Cardiovasc Pharmacol; 2007 Mar; 49(3):122-30. PubMed ID: 17414223
[TBL] [Abstract][Full Text] [Related]
19. Diabetic bladder dysfunction in T2D KK-Ay mice and its changes in the level of relevant gene expression.
Zhang J; Zhang Y; Yang X; Wang J; Xu Y; Wang R; Tan B; Huang P; Cao H
Biomed Pharmacother; 2020 Nov; 131():110706. PubMed ID: 33152907
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin: clinical effects from the LIVES Study.
Teramoto T
Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
